DS
FULC icon

DRW Securities’s Fulcrum Therapeutics FULC Stock Holding History

DRW Securities’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$126K Buy
+16,414
New +$152K ﹤0.01% 1175
2023
Q3 		– Sell
-11,000
Closed -$36K – 386
2023
Q2 		$36K Buy
+11,000
New +$32.3K ﹤0.01% 331

Other funds holding FULC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
FTM
First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

DRW Securities's FULC Position: Q1 2026 in Review

DRW Securities opened a new position in Fulcrum Therapeutics (FULC) in Q1 2026: 16,414 shares worth $126K. The stake represents ﹤0.01% of the portfolio and ranks #1175 among its holdings. This is a return to the name: DRW Securities previously reported a position in FULC as recently as Q2 2023.

DRW Securities first reported a position in FULC in Q2 2023 and has held it in 2 quarters since. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

  • DRW Securities held 16,414 shares of Fulcrum Therapeutics worth $126K as of Q1 2026.
  • Fulcrum Therapeutics was a new DRW Securities position in Q1 2026.
  • Fulcrum Therapeutics made up ﹤0.01% of DRW Securities's portfolio in Q1 2026, its #1175 holding.
  • DRW Securities first reported a position in Fulcrum Therapeutics in Q2 2023 and has held it in 2 quarters since.
  • 169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on DRW Securities's 13F filing for Q1 2026, filed 13 May 2026.